Rohan Palekar's most recent trade in Neurogene Inc was a trade of 12,050 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neurogene Inc | Rohan Palekar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 12,050 | 12,050 | - | - | Non-Qualified Stock Option (right to buy) | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.57 per share. | 17 Feb 2025 | 3,249 | 862,240 (6%) | 0% | 10.6 | 34,342 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.41 per share. | 09 Feb 2025 | 8,946 | 864,692 (6%) | 0% | 11.4 | 102,074 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 848,000 | 848,000 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 212,000 | 683,236 (4%) | 1% | 0 | Common Stock | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 200,000 | 883,236 (6%) | 1% | 0 | Common Stock | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.60 per share. | 01 Feb 2025 | 9,598 | 873,638 (6%) | 0% | 9.6 | 92,141 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 7.89 per share. | 06 Dec 2024 | 5,000 | 471,236 (3%) | 0% | 7.9 | 39,450 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 8.35 per share. | 22 Nov 2024 | 10,000 | 466,236 (3%) | 0% | 8.4 | 83,500 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.04 per share. | 17 Aug 2024 | 4,601 | 456,236 (3%) | 0% | 8.0 | 36,992 | Common Stock |
| Neurogene Inc | Rohan Palekar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 7,700 | 7,700 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 10.91 per share. | 01 Apr 2024 | 52,718 | 459,171 (3%) | 0% | 10.9 | 575,153 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 25,000 | 120,231 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 01 Apr 2024 | 25,000 | 511,889 (3%) | 0% | 1.9 | 48,250 | Common Stock |
| 89bio Inc | Palekar Rohan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 10.76 per share. | 26 Feb 2024 | 4,477 | 486,889 (3%) | 0% | 10.8 | 48,173 | Common Stock |
| 89bio Inc | Palekar Rohan | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.74 per share. | 17 Feb 2024 | 4,602 | 491,366 (3%) | 0% | 9.7 | 44,823 | Common Stock |
| 89bio Inc | Palekar Rohan | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.45 per share. | 09 Feb 2024 | 12,670 | 480,968 (3%) | 0% | 8.5 | 107,062 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 605,000 | 605,000 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Palekar Rohan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 150,000 | 498,714 (3%) | 1% | 0 | Common Stock | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.80 per share. | 01 Feb 2024 | 5,068 | 493,646 (3%) | 0% | 9.8 | 49,666 | Common Stock |
| Neurogene Inc | Rohan Palekar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 15,400 | 15,400 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Palekar Rohan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 75,000 | 376,225 (2%) | 0% | 0 | Common Stock | |
| 89bio Inc | Palekar Rohan | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.53 per share. | 05 Jan 2024 | 27,511 | 348,714 (2%) | 0% | 11.5 | 317,202 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 29 Dec 2023 | 50,000 | 351,225 (2%) | 0% | 1.9 | 96,500 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2023 | 50,000 | 145,231 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 11.20 per share. | 29 Dec 2023 | 50,000 | 301,225 (2%) | 0% | 11.2 | 560,000 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.46 per share. | 17 Aug 2023 | 4,501 | 300,950 (2%) | 0% | 15.5 | 69,585 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 33,334 | 321,978 (2%) | 0% | 0 | Common Stock | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.95 per share. | 30 Jun 2023 | 16,527 | 305,451 (2%) | 0% | 19.0 | 313,187 | Common Stock |
| Neoleukin Therapeutics Inc | Rohan Palekar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 05 Jun 2023 | 15,000 | 286,978 (2%) | 0% | 20 | 300,000 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2023 | 15,000 | 195,231 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 05 Jun 2023 | 15,000 | 301,978 (2%) | 0% | 1.9 | 28,950 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 33,333 | 302,413 (2%) | 0% | 0 | Common Stock | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.23 per share. | 31 Mar 2023 | 15,443 | 286,970 (2%) | 0% | 15.2 | 235,197 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 23 Mar 2023 | 15,000 | 269,080 (1%) | 0% | 16 | 240,000 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.97 per share. | 17 Feb 2023 | 6,279 | 284,072 (2%) | 0% | 14.0 | 87,718 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 75,000 | 290,351 (2%) | 0% | 0 | Common Stock | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.24 per share. | 05 Feb 2023 | 4,078 | 215,351 (1%) | 0% | 13.2 | 53,993 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2022 | 33,333 | 230,956 (1%) | 0% | 0 | Common Stock | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.76 per share. | 28 Sep 2022 | 11,527 | 219,429 (1%) | 0% | 5.8 | 66,396 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 08 Sep 2022 | 100,000 | 197,623 (1%) | 0% | 1.9 | 193,000 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2022 | 100,000 | 225,231 | - | - | Stock Option (Right to Buy) | |
| Neoleukin Therapeutics Inc | Rohan Palekar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Neoleukin Therapeutics Inc | Rohan Palekar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 220,000 | 220,000 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 54,200 | 100,045 (0%) | 0% | 0 | Common Stock | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.23 per share. | 05 Feb 2022 | 4,088 | 95,957 (0%) | 0% | 5.2 | 21,380 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 7.50 per share. | 27 Jan 2022 | 5,000 | 43,345 (0%) | 0% | 7.5 | 37,500 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 6.14 per share. | 27 Jan 2022 | 2,500 | 45,845 (0%) | 0% | 6.1 | 15,350 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 17.07 per share. | 07 Jul 2021 | 5,000 | 35,000 (0%) | 0% | 17.1 | 85,350 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 17.07 per share. | 07 Jul 2021 | 5,000 | 35,000 (0%) | 0% | 17.1 | 85,350 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 16.25 per share. | 07 Jul 2021 | 2,000 | 37,000 (0%) | 0% | 16.3 | 32,500 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 16.25 per share. | 07 Jul 2021 | 2,000 | 37,000 (0%) | 0% | 16.3 | 32,500 | Common Stock |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 203,750 | 203,750 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Rohan Palekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 30,000 | 30,000 (0%) | 0% | 0 | Common Stock |